Search Within

Howard Scher

Formats
  1. Journal Article (624)
  2. Meeting Abstract (463)
  3. Book Section (13)
  4. Conference Paper (11)
  5. Editorial (6)
  6. Review (6)
  7. Guidelines (3)
  8. Correspondence (2)
  9. Research Letter (2)
Groups
  1. Department of Medicine (1130)
  2. Genitourinary Oncology Service (1130)
  3. Solid Tumor Oncology Division (1130)
  4. GSK Faculty (305)
  5. Sloan Kettering Institute Faculty (249)
  6. Molecular Pharmacology and Chemistry Program Faculty (229)

More Groups

People
  1. Michael Morris (217)
  2. Susan Slovin (140)
  3. Dana Rathkopf (133)
  4. Daniel Danila (111)
  5. Steven Larson (110)
  6. Victor Reuter (97)

More People

Years
  1. 2025 (8)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (25)
  5. 2021 (19)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (328)
  2. Clinical Cancer Research (85)
  3. Cancer Research (54)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (47)
  5. Journal of Urology (36)
  6. European Urology (35)

More Publications

Publishers
  1. American Society of Clinical Oncology (335)
  2. American Association for Cancer Research (197)
  3. Elsevier Science, Inc. (119)
  4. Elsevier Inc. (72)
  5. Nature Publishing Group (58)
  6. Oxford University Press (47)

More Publishers

Results (1130)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Carbone, E.; Fernandez, C.; Chen, Y.; Autio, K. A.; Rathkopf, D. E.; Kampel, L.; Morris, M. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A)
    Meeting Abstract

    Scher, H. I.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R. P.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical versus radiographic progression and overall survival for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from COU-AA-302
    Meeting Abstract

    Ryan, C. J.; Kheoh, T.; Scher, H. I.; De Porre, P.; Yu, M. K.; Morris, M. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer
    Meeting Abstract

    Razavi, P.; Li, B.; Abida, W.; Aravanis, A.; Jung, B.; Shen, R.; Hou, C.; De Bruijn, I.; Gnerre, S.; Lim, R. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Trop-2 expression on treatment resistant cancer cells in castrate-resistant prostate cancer (CRPC) as a predictive biomarker for targeted therapy
    Meeting Abstract

    Ku, K. P.; Lang, J. M.; Sperger, J.; Dehm, S.; Kohli, M.; Wang, L.; Wang, L.; Tagawa, S. T.; Scher, H. I.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials
    Meeting Abstract

    Heller, G.; McCornnack, R. T.; Kheoh, T.; Smith, M. R.; Dreicer, R.; Saad, F.; De Wit, R.; Aftab, D. T.; Hirmand, M.; MacLean, D. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx)
    Meeting Abstract

    Dittamore, R. V.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment
    Meeting Abstract

    Basch, E. M.; Deal, A. M.; Dueck, A. C.; Bennett, A. V.; Atkinson, T. M.; Scher, H. I.; Kris, M. G.; Hudis, C. A.; Sabbatini, P.; Dulko, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Translating prostate cancer working group (PCWG) criteria into a quantitative progression biomarker in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Anand, A.; Heller, G.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Observational longitudinal study of pain in men with metastatic castrate-resistant prostate cancer: Aim 1. Rates of pain palliation and pain progression as indicated by self-reported daily pain and analgesic use
    Meeting Abstract

    Bennett, A. V.; Shouery, M.; Wang, M.; Whang, Y. E.; Milowsky, M.; Drier, S.; Carr, P.; Graff, J. N.; Morris, M. J.; Scher, H. I.; more...
    Quality of Life Research (2017)

    Fulltext@MSK | Save